

Bavarian Biotech News

October 2022



Bavaria

*Tradition
meets*

Innovation

© Wolfisler/Shutterstock

DEAR READER

Page 2

BAVARIA WORLDWIDE

Page 8/9

RECENT HEADLINES

Page 3-6

BIOENTREPRENEURS IN BAVARIA

Page 10/11

SPOTLIGHT DIGITIZATION

Page 7

EVENTS & CONTACT

Page 12

Dear Reader,



after a two-year break due to the pandemic, the Munich Oktoberfest took place again this autumn. The world's largest folk festival is one of the outstanding Bavarian traditions. Our cover photo shows the festively decorated carriage of a brewery entering the festival grounds.

The meeting of so many people in a party mood naturally also entails various challenges such as first aid on site. To improve medical care, a computer tomograph (CT) was used for the first time this year directly on-site at the Munich Oktoberfest to decide how to further treat injured visitors. The Munich start-up deepc and the University Hospital of Munich (LMU) provided this radiology AI for use in first aid.

Furthermore, the Fraunhofer Institute IBP carried out an experiment in an Oktoberfest tent, largely unnoticed by the visitors. The effectiveness of UVC light against airborne germs was tested here. UVC technology has reduced the number of airborne germs capable of multiplying by 27 percent.

You can find more about Bavarian innovations and news from the field of life sciences in our current newsletter.

And on our own behalf – as of 2023, we will have a change in management at Bio^M.

Read more below and have fun browsing!

Your Bio^M team

Prof. Ralf Huss appointed as new managing director of Bio^M

Prof. Dr. Ralf Huss will become the new managing director of Bio^M Biotech Cluster Development GmbH, effective of January 1st, 2023, succeeding Prof. Dr. Horst Domdey, who will be retiring.

Prof. Huss has many years of experience in academic research and international pharmaceutical companies. After his studies in medicine and research stays in Switzerland and the USA with a focus on immunology, as well as cancer and stem cell research, he specialized in pathology and became professor at the Ludwig Maximilian University (LMU) Munich. From 2005 to 2011, he worked in Pharma Research & Early Development at Roche Diagnostics, Penzberg, before co-founding apceth in Munich, where he served as Chief Scientific Officer



© private

In 2015, Huss joined Definiens as Chief Medical Officer. Since 2020, he has been Managing Senior Physician at the Institute of Pathology and Molecular Diagnostics, since 2021 Director of the Institute of Digital Medicine (IDM) and most recently also Deputy Medical Director at Augsburg University Hospital.

As of January 1st, 2023, Prof. Huss will take over as Managing Director of Bio^M Biotech Cluster Development GmbH, the network organization of the biotechnology industry in Munich and Bavaria since 1997. Prof. Horst Domdey, who co-founded the biotech cluster organization and successfully led it for 25 years, will be retiring.

deepc supports emergency care at the Munich Oktoberfest 2022 with AI

Munich-based start-up **deepc** and **LMU Klinikum München** supplied radiology AI for use in first aid at the world's largest public festival "Oktoberfest". The specially developed algorithms support on-site medical diagnostics in the field of computed tomography and enable faster diagnosis of brain hemorrhages while increasing patient safety.



© deepc/LMU Klinikum

This year, for the first time, a **computer tomograph (CT) scanner** was used on-site at the Munich Oktoberfest to triage injured visitors. Visitors with bleeding head wounds or other head injuries could thus be examined directly on site and did not have to be taken to the emergency room of a hospital by ambulance.

The responsible medical team of the [Department of Radiology at LMU University Hospital of Munich](#) relies on the use of artificial intelligence (AI): The health IT company [deepc](#) is equipping the facility with leading algorithms for CT examinations of the head.

deepc has developed the **radiology AI platform deepcOS**. Physicians can use it to access a variety of regulatory-approved and world-leading AI solutions. The use of AI can lead to faster reporting and more efficient workflows and offers radiologists more security in their daily routine. [Read more...](#)

Brainlab AG nominated for German Future Prize

Stefan Vilsmeier and **Claus Promberger** from Brainlab, a leading provider in the field of digital medical technology, and **Prof. Cordula Petersen** from the UKE in Hamburg, have been nominated for the German Future Prize 2022 "Prize of the Federal President for Technology and Innovation" with the technology **ExacTrac Dynamic®**, an improved radiation method specifically for lung cancer patients.

[Brainlab](#) is nominated for an **improved radiation method** specifically for lung cancer patients. In these patients in particular, irradiation is complicated because the tumor is constantly moving as the patient breathes. The new technology enables millimeter-precise detection of the patient's position during radiation treatment and verification of the tumor's position using real-time data.

The treatment ray can thus be controlled according to the tumor position, reducing damage to surrounding healthy tissue. This is expected to enable faster treatment with fewer side effects than conventional radiation treatments.

[Read more...](#)



Nominees of the German Future Prize: Stefan Vilsmeier and Dipl.-Inf. Claus Promberger, both Brainlab AG, Munich, and Prof. Dr. med. Cordula Petersen, University Medical Center Hamburg-Eppendorf (UKE) © Deutscher Zukunftspreis, Ansgar Pudenz

Start of the Bavaria-wide Oncological Radiology Network - BORN

The Bavaria-wide Oncological Radiology Network - 'BORN' for short - of the BZKF uses the opportunities of digitization for the care of cancer patients.

The aim is to perform imaging diagnostics for tumor diseases uniformly throughout Bavaria, starting at the university hospitals and to evaluate them in a structured manner. Therefore, a secure IT structure for data collection and exchange will be provided by Brainlab AG from Munich with its subsidiary Mint Medical GmbH. to develop a secure IT structure for data collection and exchange. After testing at the six university hospitals, the standardized collection of imaging data can be transferred to other hospitals and practices in the future, benefiting patients throughout Bavaria. In the **BZKF BORN project**, the radiology institutes of the six Bavarian university hospitals work closely together under the umbrella of the Bavarian Center for Cancer Research (BZKF).

[Read more...](#)



BZKF BORN Steering Group, Directors of the BZKF Radiology Clinics Prof. Dr. Michael Uder, Prof. Dr. Marcus Makowski, Prof. Dr. Thorsten Bley, Prof. Dr. Thomas Kröncke, Prof. Dr. Christian Stroszczynski (LTR), not in picture Prof. Dr. Jens Ricke © K. Czoppelt/ Klinikum rechts der Isar

Andera Partners: EUR 456 million for its largest life sciences fund

Andera Life Sciences has announced the closing of the EUR 456 million financing round of its BioDiscovery-6 fund.

With the now sixth generation of BioDiscovery funds, [Andera Partners](#) confirms its position as one of the leading venture capitalists for life sciences in Europe. The existing institutional investors of the BioDiscovery funds are again involved. They have been joined by new subscribers, which include funds of funds, insurance companies, pension funds, family offices, private investors and pharmaceutical companies.



© Pixabay

Andera Life Sciences is the business unit specialized in innovative therapies and medical technologies of the investment company Andera Partners, which is based in Paris and Munich, among others.

With this new fund, the management team intends to continue its focused investment strategy focused on building a balanced portfolio of innovative companies developing therapeutics and medical technologies, at all stages of their development, in Europe and the United States. To date, BioDiscovery 6 has made six investments in Evommune, Amolyt, TargED, Tubulis, Mineralys and Imcheck. [Read more...](#)

Benjamin Knier honored with prestigious Sobek Young Investigator Award for Multiple Sclerosis Research

The Sobek Foundation has now honored its award winners for the years 2020 to 2022. With the Young Investigator Award 2020, the Sobek Foundation honored the research work of PD Dr. Benjamin Knier from the Clinic and Polyclinic for Neurology at the Klinikum rechts der Isar of the Technical University of Munich (TUM). Using optical coherence tomography, Dr. Knier succeeded in demonstrating that visible changes in the retina already occur in the preliminary stages of MS, which can provide clues to the later course of the disease.

Due to the pandemic, the [Roman, Marga and Mareille Sobek Foundation](#) honored its award winners for the years 2020 to

2022. With an endowment of 100,000 euros, the Sobek Research Prize is Europe's highest award in the field of basic research into multiple sclerosis and is awarded for a lifetime's achievement.

The 2020 Young Investigator Award was awarded to **Dr. Benjamin Knier** from the Clinic and Polyclinic for Neurology at the Klinikum rechts der Isar of the Technical University of Munich (TUM) for his research work. Dr. Knier has been a senior physician at the Department of Neurology at the University Hospital rechts der Isar and head of the Neuroophthalmology research group since his habilitation in 2019. Using optical coherence tomography (OCT), he succeeded in demonstrating that visible **changes in the retina** already occur in the preliminary stages of MS, which can provide clues to the later course of the disease.



Sobek Young talent award winner 2020 PD Dr. Benjamin Knier, Laudator Prof. Dr. Klaus V. Toyka, both Sobek Young talent award winner 2022 Prof. Dr. Anne-Katrin Pröbstel and Prof. Dr. Lucas Schirmer (LTR) © AMSEL e.V. / Frank Eppler

adivo: EUR 2.5 million EU funding for therapies against inflammatory bowel disease in companion animals

Martinsried-based adivo GmbH has been awarded a EUR 2.5 million European Innovation Council (EIC) Accelerator Grant to support its therapeutic antibody program for novel therapeutic options for dogs with inflammatory bowel disease.

[adivo](#) aims to launch a new era for companion animal health with its proprietary **phage display antibody libraries**. The libraries will serve as basis for the development of species-specific drugs against cancer, chronic inflammatory diseases and other serious diseases in companion animals.



Dr. Kathrin Ladetzki-Baehs and Dr. Markus Waldhuber, both founder and CEO of adivo GmbH © Adivo GmbH

With the funding, adivo aims to accelerate its therapeutic antibody program, which addresses the growing need for novel therapeutic options for **dogs with inflammatory bowel disease (IBD)**.

With CEASAR, adivo has developed the first fully canine phage display platform in the veterinary market for the selection of therapeutic candidates against a broad spectrum of diseases. Recently, the company expanded its technology basis to cover a second companion animal species with significant medical needs and launched FELIX, the first fully synthetic source of therapeutic antibodies on the market to date for cats. The adivo technology platforms allows de-novo identification of species-specific antibodies panels to select drug candidates with optimal functionality, developability and low risk of immunogenicity. [Read more...](#)

Dr. Camilla Rothe honored with Order of Merit of the Federal Republic of Germany

For her research in the context of the Corona pandemic, the physician **Dr. Camilla Rothe** from the Tropical Institute of the LMU Hospital in Munich received the Order of Merit of the Federal Republic of Germany.

Dr. Camilla Rothe conducts research as a specialist in internal medicine, tropical medicine and infectious diseases and as deputy head of the Department of Infectious and Tropical Medicine (Tropical Institute) at the LMU Hospital in Munich. For her commitment during the Corona pandemic, she has now been honored with the Order of Merit of the Federal Republic of Germany.



Dr. Camilla Rothe from the Tropical Institute of the LMU University Hospital was one of the first to prove asymptomatic COVID-19 transmission. © LMU

She was one of the first to prove **asymptomatic COVID-19 transmission**. Rothe had diagnosed the first Corona infection in Germany on January 27, 2020. She recognized that the infection came from a person who was asymptomatic herself at the time. The publishing of these findings together with the director of the Munich Tropical Institute triggered a scientific dispute worldwide, at the end of which was the confirmation of her findings.

[Read more...](#)

Prof. Clemens Wendtner receives Bavarian Order of Merit for commitment against COVID-19

Prof. Clemens Wendtner receives the Bavarian Order of Merit for his dedication in the fight against COVID-19 from Bavarian Minister President Markus Söder.

With his team, **Clemens Wendtner**, chief physician of infectious diseases at München Klinik Schwabing, treated the first COVID-19 patients in Germany in 2020. In the meantime, more than 7000 have already been treated in the five Munich clinics. In addition to his work as a physician and his scientific activities on the topic of SARS-CoV-2, he has been advising the Federal Ministry of Health (BMG) in Berlin, the Bavarian State Ministry of Health and Care (StMG) on aspects of COVID-19 since 2020.



Prof. Dr. Clemens Wendtner receives the Bavarian Order of Merit from Bavarian Prime Minister Markus Söder in the Antiquarium of the Munich Residence © Bayerische Staatskanzlei

As a sign of honorable and grateful recognition for outstanding service to the Free State of Bavaria and the Bavarian people, Wendtner will receive the Bavarian Order of Merit. In addition to Wendtner, Minister President Markus Söder honored more than 70 other persons with the award. [Read more...](#)

DigiMed Bayern Symposium outlines the path to a "medicine of the future"

Munich-based Bio^M Biotech Cluster Development GmbH and the Deutsches Herzzentrum München hosted the annual DigiMed Bayern Symposium 2022: Big Data and AI: Can Medicine Do the Doable? on October 6 at the Gene Center Munich. This year, the DigiMed Bayern partners discussed together with top-class speakers from international politics, medical research, and industry: about successful project examples for P4 medicine, about infrastructure and pilot projects for the use of digital health data and about Germany's progress in the field of "Digital Health" in international comparison.



Dr. Thomas Huber (StMGp), Anja Kroke (DigiMed Bayern/Bio^M), Joanna Wardzinski (AWS), Prof. Horst Domdey (Bio^M) and Prof. Schunkert (Deutsches Herzzentrum München), (from left).

The Bavarian flagship project **DigiMed Bayern** aims to prevent heart attacks and strokes and represents data-based personalized medicine - using the widespread disease atherosclerosis as an example. The flagship project, which has been funded by the Bavarian State Ministry of Health and Care with a total volume of 24.5 million euros since 2018, pursues as the so-called P4 medicine. The goal is a personalized (tailored), preventive (avoiding), predictive (predicting) and participatory (participating) medicine of the future. This year, the top-class DigiMed Bayern Symposium highlighted the potential of digital medicine in three sessions: From the successful use of health data from the Vroni study for the prevention of early genetic diseases in children to the mobile health app *HerzFit*, which enables users to manage their heart health (participatory). P4 medicine projects were also outlined, which aim to enable personalized medicine by incorporating clinical and omics data, as well as data from epidemiological and clinical studies. Both ethically and legally, the responsible use of personal and digitized health data was discussed.



About DigiMed Bayern

The DigiMed Bayern flagship project started at the end of 2018 with approximately 22 million euros in funding from the Bavarian State Ministry of Health and Care (StMGp) as part of the BAYERN DIGITAL II master plan. The project goal is to integrate P4 medicine (predictive, preventive, personalized, participatory) in the specific indication of atherosclerosis into everyday clinical practice. The ultimate aim is to improve the prediction of disease risks, targeted prevention as well as diagnosis and therapy. To this end, extensive health data of patients with atherosclerosis are collected and analysed. The scientific director of DigiMed Bayern is Prof. Heribert Schunkert from the Deutsches Herzzentrum München. Bio^M Biotech Cluster Development GmbH is responsible for the management and project coordination. World-leading consortium partners from Bavaria such as hospitals, patient organizations and research institutions are also involved in the project.

More information at: www.digimed-bayern.de.




@DigiMedBayern
#digimed22

Osaka and Munich continue their successful partnership

The cluster management organizations Bio^M, Munich, Germany, and Osaka Bio Headquarters, Osaka, Japan, officially announced the renewal of their long-standing Transnational Biotech & Life Sciences Cooperation Partnership Agreement at the EU-Japan Biotech & Pharma Partnering Conference 2022 in Osaka.

Considering the numerous deals and long-term partnerships between Bavarian biotech companies and Japanese pharmaceutical companies, it reveals that Japan is almost as attractive for the regional sector as the pharmaceutical industry in the USA. Building up on this mutual interest, the **Munich-Osaka Partnership Agreement** combines Osaka's large accumulation of pharmaceutical companies and renowned scientific expertise with the innovative biopharma technologies from start-ups and SMEs in Bavaria.

The Agreement sets concrete actions with the aim to accelerate business in both regions, to inform each other about the newest developments in technologies, industry and academia, and to support business matchmaking and trade missions between Osaka and Munich. [Read more...](#)




The cluster representatives Dr. Hiroyuki Akatsuka of Osaka Bio Headquarters (left) and Dr. Max Pöhlmann, Bio^M (right) at the renewal of their long-standing transnational biotech & life sciences cooperation agreement. © Osaka Prefectural Government

Bavarian biotechs back at BioJapan, Yokohama

For the first time since the beginning of the Corona-Pandemic, Japan's most important partnering conference for the Biotech sector, the BioJapan, was able to make a successful comeback from October 12 to 14, 2022. As in previous years, Bavarian companies presented themselves to the Japanese market under the auspices of the German joint booth.

Asia's largest partnering event, consisting of an exhibition, a series of sector specific seminars and partnering opportunities was finally able to welcome participants from all over the world again. As Bavarian representatives, Ascenion, Bicoll GmbH, Iris Biotech, Sirion Biotech and the Bavarian Biotech Cluster organization Bio^M traveled to Yokohama to present their newest developments, products and ideas to long-lasting partners, new clients and an interested audience. Although the number of visitors was certainly a little lower than usual, there was a lot of interest and many good discussions. The participants from Bavaria were very satisfied with the event and noted that a regular presence is very important, especially for the Japanese market.

Picture top right: the German booth at BioJapan, Yokohama 2022
Bottom right picture: The Bavarian representatives at the German booth at BioJapan, Yokohama 2022



BIO-Europe – from Leipzig 2022 to Munich 2023

This year, the industry’s largest gathering of biopharma professionals, the BIO-Europe 2022, took place in Leipzig from October 24 – 26. Bio^M was happy to host a total of eight Bavarian biotech companies at the booth of the Bavarian Biotech Cluster: [Assay.Works](#) | [lifespın GmbH](#) | [2bind GmbH](#) | [HWI group](#) pharma services GmbH | [NDA Regulatory Service GmbH](#) of [NDA Group AB](#) | [microPhotonX](#) | [OmicScouts GmbH](#) | [PAN-Biotech GmbH](#)

Many lively exchanges took place not only at the booth, but also in partnering-meetings, over lunch or at the numerous social events in the evenings.

Bio^M supported the partnership between Germany and Korea at BIO-Europe2022 and introduced the Bavarian Biotech Cluster to the participating companies and organizations at the KOREA-EU Networking Dinner. Dr. Stephanie Wehnelt presented Bio^M's achievements and visions and promoted the cooperative exchange between Korean and German companies within the biotech and pharma sector. In 2023, BIO-Europe will return once again to Munich. André Hofmann, CEO of biosaxony, officially handed over to Bio^M's managing director, Prof. Horst Domdey. Bio^M will thus become the cluster host for the upcoming BIO-Europe 2023 in Munich.



Anna Chrismann, EBD Group, André Hofmann, Biosaxony and Horst Domdey, Bio^M (right) at the handover at BIO-Europe

EU Delegation of Cluster Organizations and SME at Singapore

On October 18 - 20, 2022, the European Commission, Directorate General for Internal Market, Industry, Entrepreneurship and SMEs (DG GROW) and Enterprise Singapore (Enterprise SG) organized the EU-Singapore matchmaking event for cluster organizations and SMEs from the European Union (EU) and Singapore. The mission was supported by the EU Delegation to Singapore and the Singapore Ministry of Trade and Industry, which was facilitated by the European Cluster Collaboration Platform (ECCP) and the Enterprise Europe Network (EEN).



The event aimed to support cluster cooperation for strategic business partnerships taking advantage of the provisions of the Free Trade Agreement (EUSFTA) signed between the European Union and Singapore in October 2018 (implemented in November 2019). Participants were focused on identifying potential areas of common interest for cooperation and synergies, in terms of the sectoral, value chain, and market focus of their SMEs and other companies. In addition, they aimed to improve the EU-Singapore industry and academia-industry collaboration in research, development, and innovation.

The two-day official agenda of the event took part on site in Singapore, in the frame of the 5th edition of [Industrial Transformation ASIA-PACIFIC – a HANNOVER MESSE events \(ITAP\)](#).

The EU delegation included 24 members, representing different cluster organizations and SMEs from 10 EU countries (Bulgaria, Czechia, France, Germany, Lithuania, Poland, Portugal, Romania, Spain, Sweden). A total of 76 participants, including Singaporean organizations (both cluster organizations and SMEs), held 176 bilateral meetings during the matchmaking sessions.

IRUBIS: EUR 2.8 million seed funding for real-time measurement of bioprocesses

Biotech start-up Irubis has closed a EUR 2.8 million seed funding round. The company aims to automate process development and manufacturing of biopharmaceutical drugs and has developed a technology that is a plug-and-play system that simplifies automated measurement of metabolites and nutrients in cell cultivation and protein quantity and quality parameters in purification.

Investors are [High-Tech Gründerfonds](#) (HTGF), [Verve Ventures](#) and [Ventura BioMed](#) as well as

[EIC Fund](#), the [Initiative for Industrial Innovators](#) and other business angels from the biotech industry or the Munich startup scene. **Irubis** innovative **process analytical technology (PAT) Monipa**, is based on mid infrared spectroscopy. The real-time monitoring system has been developed in close partnership with biopharma companies. The plug-and-play system simplifies the prediction of metabolites and nutrients in cell cultivations and protein quantity and quality parameters in purification. Process monitoring and control enables higher yield, better quality and shortens the overall process development.

[Read more...](#)



Founding team of IRUBIS: Lorenz Sykora-Mirle, Anja Müller and Alexander Geißler (from left). © IRUBIS.

Munich-based Lumatix Biotech wins BioRiver Boost! Competition

The start-up Lumatix Biotech wins the BioRiver Boost! With its light-controlled antibody purification, the start-up company from Garching near Munich won first place and was thus selected as the most promising start-up of 2022.

For the ninth time in a row, the annual European start-up competition **BioRiver Boost!** awarded the three best young companies. The award ceremony took place at the headquarters of this year's host, QIAGEN GmbH. The three winning teams win individually tailored coaching by

experienced entrepreneurs, marketing support from experts and access to the BioRiver network with business contacts.

1st place: Antibody purification by light

The start-up **Lumatix Biotech** from Garching produces affinity matrices for the purification of monoclonal antibodies - light-controlled and without the use of chemicals. Lumatix Biotech founders **Andreas Reichert** and team member **Ingmar Polte** also want to bring their technology further into application with new partners from the BioRiver network. After all, the principle is very broadly applicable, as Polte explains, "We could use it to purify all biomolecules - from viral particles to proteins - very gently and efficiently."

[Read more...](#)



Dr. Benedict Doorschodt, Prof. Dr. René Tolba (both Vivalyx, 3rd place), Andreas Reichert, Ingmar Polte (both Lumatix Biotech, 1st place), Patrick Bongartz, Konstantin Kurz (both BioThrust, 2nd place)
© BioRiver

Dermagnostix: new capital for better diagnosis of psoriasis and eczema

Dermagnostix, based in Friedberg and Freiburg, Germany, has successfully closed its EUR 4.6 million seed-plus financing round. The fresh capital will be used for the market launch of its first products for the diagnosis of skin diseases and the development of future diagnostic tests.

Dermagnostix is developing a fully automated microfluidics-based diagnostic platform for dermatology. In the past months, the start-up has developed its first product **PsorX** for the upcoming

market entry. Basis is the molecular test "PsorEx" patented by **Helmholtz Munich** and **Technical University of Munich** to distinguish between psoriasis and eczema. Together with Hahn-Schickard in Freiburg and their LabDisk platform, the idea was technically optimized. The fresh capital will now be used to roll out PsorX-LabDisk and LabDisk-Analyzer in Germany and Europe and to expand the test menu in the area of skin cancer and chronic inflammatory skin diseases.

With PsorX, the world's first test for distinguishing psoriasis and eczema at the molecular level, Dermagnostix aims to advance diagnostics in dermatology, which are still largely based on a subjective visual examination, and thus link up with developments in therapy. Modern molecular diagnostics are urgently needed to complement conventional diagnostics. [Read more...](#)



HMNC Brain Health Raises EUR 14.3 million to advance precision psychiatry therapies

HMNC Brain Health, a clinical stage biopharma company in Munich pioneering precision psychiatry has raised an additional EUR 14.3 million in a funding series, bringing the total capital raised to date to EUR 42.3 million. The round comprised of new and former investors, including Dr. Josef Ackermann, Wilhelm Beier, Toni Kroos, and Carsten Maschmeyer. It is the First of Two Expected Closings of Round that increases the total capital raised to date to 42.3 Million euros.



HMNC Brain Health (HMNC Holding GmbH) is a clinical stage **precision psychiatry** biopharma company, pioneering the **development of personalized therapies**, powered by its AI platform and predictive companion diagnostics suite, bringing substantial therapeutic benefit to selected patient populations suffering from mental health disorders.

The additional funding of EUR 14.3 million was raised from existing investors, including Carsten Maschmeyer, the Jahr Group and Guntard Gutmann, bringing the total capital raised to date to EUR 42.3 million. The round also included new investors **Dr. Josef Ackermann** (formerly CEO of Deutsche Bank), **Toni Kroos** (Real Madrid), **Wilhelm Beier** (Dermapharm) and **Hans Kompernaß** (Hans Kompernaß GmbH).

The proceeds will be used to accelerate HMNC's precision psychiatry programs, in which first-in-class pharmaceuticals are co-developed with proprietary genetic companion diagnostics to identify the patient groups most likely to benefit most from these treatments. [Read more...](#)

[BIO-Europe Leipzig](#)

November 2 - 4, 2022 | Virtual

[BIO-Europe Spring](#)

March 20 - 22, 2023 | Basel, Switzerland

March 28 - 30, 2023 | Digital

[Biovaria](#)

April 24 - 25, 2023 | Munich, Germany

[BIO International Convention](#)

June 5 - 8, 2023 | Boston, USA

[BIO-Europe Munich](#)

November 6 - 8, 2023 | Munich, Germany

Please find current event information on our website www.bio-m.org/en/events.

Contact

Bio^M Biotech Cluster Development GmbH
Am Klopferspitz 19a
82152 Martinsried, Munich, Germany



www.bio-m.org



+49 (0) 89 89 96 790



info@bio-m.org

Follow us on:



Editorial staff



Gabriele Klingner
klingner@bio-m.org



Dr. Christina Grimm
grimm@bio-m.org

International Affairs



Dr. Stephanie Wehnelt
Wehnelt@bio-m.org

Founders & Investors



Dr. Petra Burgstaller,
Burgstaller@bio-m.org



Christina Enke-Stolle
Enke-Stolle@bio-m.org

All pictures by Bio^M or as indicated